Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon May 23, 2013 2:11pm

185 Views

Post# 21432893

RE: RE: RE: RE: RE: RE: Effective date

It is now clear that one can buy on May 31st and still be included, based on these Due Bill trading procedures. But there is one statement that still confuses me: "in the period two days prior to the Distribution Record Date up to and including the payment date of the Newco Shares......" So does this mean that Monday June 3rd is in play as well for being eligible (assuming that June 3rd remains as the effective date)?

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity